Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 80

1.

The immune system in irritable bowel syndrome.

Barbara G, Cremon C, Carini G, Bellacosa L, Zecchi L, De Giorgio R, Corinaldesi R, Stanghellini V.

J Neurogastroenterol Motil. 2011 Oct;17(4):349-59. doi: 10.5056/jnm.2011.17.4.349. Epub 2011 Oct 31.

2.

Mucosal permeability and immune activation as potential therapeutic targets of probiotics in irritable bowel syndrome.

Barbara G, Zecchi L, Barbaro R, Cremon C, Bellacosa L, Marcellini M, De Giorgio R, Corinaldesi R, Stanghellini V.

J Clin Gastroenterol. 2012 Oct;46 Suppl:S52-5. doi: 10.1097/MCG.0b013e318264e918.

PMID:
22955358
3.

Tight junctions and IBS--the link between epithelial permeability, low-grade inflammation, and symptom generation?

Piche T.

Neurogastroenterol Motil. 2014 Mar;26(3):296-302. doi: 10.1111/nmo.12315. Review.

PMID:
24548256
4.

Cellular and molecular basis of intestinal barrier dysfunction in the irritable bowel syndrome.

Martínez C, González-Castro A, Vicario M, Santos J.

Gut Liver. 2012 Jul;6(3):305-15. doi: 10.5009/gnl.2012.6.3.305. Epub 2012 Jul 12.

5.

Aminosalicylates and other anti-inflammatory compounds for irritable bowel syndrome.

Barbara G, Stanghellini V, Cremon C, De Giorgio R, Fronzoni L, Serra M, Corinaldesi R.

Dig Dis. 2009;27 Suppl 1:115-21. doi: 10.1159/000268131. Epub 2010 Mar 4. Review.

PMID:
20203507
6.

Antiflagellin antibodies suggest infective participation in irritable bowel syndrome pathogenesis.

Cremon C, Pallotti F, Bacchilega M, Stanghellini V, Corinaldesi R, Barbara G.

Expert Rev Gastroenterol Hepatol. 2008 Dec;2(6):735-40. doi: 10.1586/17474124.2.6.735.

PMID:
19090734
7.

Intestinal serotonin release, sensory neuron activation, and abdominal pain in irritable bowel syndrome.

Cremon C, Carini G, Wang B, Vasina V, Cogliandro RF, De Giorgio R, Stanghellini V, Grundy D, Tonini M, De Ponti F, Corinaldesi R, Barbara G.

Am J Gastroenterol. 2011 Jul;106(7):1290-8. doi: 10.1038/ajg.2011.86. Epub 2011 Mar 22.

PMID:
21427712
8.

Intestinal dysbiosis in irritable bowel syndrome: etiological factor or epiphenomenon?

Cremon C, Carini G, De Giorgio R, Stanghellini V, Corinaldesi R, Barbara G.

Expert Rev Mol Diagn. 2010 May;10(4):389-93. doi: 10.1586/erm.10.33.

PMID:
20465494
9.

Diarrhoea-predominant irritable bowel syndrome: an organic disorder with structural abnormalities in the jejunal epithelial barrier.

Martínez C, Lobo B, Pigrau M, Ramos L, González-Castro AM, Alonso C, Guilarte M, Guilá M, de Torres I, Azpiroz F, Santos J, Vicario M.

Gut. 2013 Aug;62(8):1160-8. doi: 10.1136/gutjnl-2012-302093. Epub 2012 May 25.

PMID:
22637702
10.

Aberrant mucosal lymphocyte number and subsets in the colon of post-infectious irritable bowel syndrome patients.

Sundin J, Rangel I, Kumawat AK, Hultgren-Hörnquist E, Brummer RJ.

Scand J Gastroenterol. 2014 Sep;49(9):1068-75. doi: 10.3109/00365521.2014.926982. Epub 2014 Jun 12.

PMID:
24919810
11.

Increased serum levels of lipopolysaccharide and antiflagellin antibodies in patients with diarrhea-predominant irritable bowel syndrome.

Dlugosz A, Nowak P, D'Amato M, Mohammadian Kermani G, Nyström J, Abdurahman S, Lindberg G.

Neurogastroenterol Motil. 2015 Dec;27(12):1747-54. doi: 10.1111/nmo.12670. Epub 2015 Sep 21.

PMID:
26387872
12.

The putative role of the intestinal microbiota in the irritable bowel syndrome.

Collins SM, Denou E, Verdu EF, Bercik P.

Dig Liver Dis. 2009 Dec;41(12):850-3. doi: 10.1016/j.dld.2009.07.023. Epub 2009 Sep 8. Review.

PMID:
19740713
13.

[Irritable Bowel Syndrome, Emotion Regulation, and Gut Microbiota].

Fukudo S.

Brain Nerve. 2016 Jun;68(6):607-15. doi: 10.11477/mf.1416200448. Japanese.

PMID:
27279158
14.

Postinfectious irritable bowel syndrome.

Barbara G, Cremon C, Pallotti F, De Giorgio R, Stanghellini V, Corinaldesi R.

J Pediatr Gastroenterol Nutr. 2009 Apr;48 Suppl 2:S95-7. doi: 10.1097/MPG.0b013e3181a15e2e. Review.

PMID:
19300138
15.

Irritable bowel syndrome: methods, mechanisms, and pathophysiology. The confluence of increased permeability, inflammation, and pain in irritable bowel syndrome.

Camilleri M, Lasch K, Zhou W.

Am J Physiol Gastrointest Liver Physiol. 2012 Oct;303(7):G775-85. doi: 10.1152/ajpgi.00155.2012. Epub 2012 Jul 26. Review.

PMID:
22837345
16.

Review article: evidence for the role of gut microbiota in irritable bowel syndrome and its potential influence on therapeutic targets.

Dupont HL.

Aliment Pharmacol Ther. 2014 May;39(10):1033-42. doi: 10.1111/apt.12728. Epub 2014 Mar 25. Review.

17.

Sensory neuro-immune interactions differ between irritable bowel syndrome subtypes.

Hughes PA, Harrington AM, Castro J, Liebregts T, Adam B, Grasby DJ, Isaacs NJ, Maldeniya L, Martin CM, Persson J, Andrews JM, Holtmann G, Blackshaw LA, Brierley SM.

Gut. 2013 Oct;62(10):1456-65. doi: 10.1136/gutjnl-2011-301856. Epub 2012 Jul 5.

PMID:
22767422
18.

Review article: Associations between immune activation, intestinal permeability and the irritable bowel syndrome.

Matricon J, Meleine M, Gelot A, Piche T, Dapoigny M, Muller E, Ardid D.

Aliment Pharmacol Ther. 2012 Dec;36(11-12):1009-31. doi: 10.1111/apt.12080. Epub 2012 Oct 15. Review.

19.

New pathophysiological mechanisms in irritable bowel syndrome.

Barbara G, De Giorgio R, Stanghellini V, Cremon C, Salvioli B, Corinaldesi R.

Aliment Pharmacol Ther. 2004 Jul;20 Suppl 2:1-9. Review.

20.

Altered faecal and mucosal microbial composition in post-infectious irritable bowel syndrome patients correlates with mucosal lymphocyte phenotypes and psychological distress.

Sundin J, Rangel I, Fuentes S, Heikamp-de Jong I, Hultgren-Hörnquist E, de Vos WM, Brummer RJ.

Aliment Pharmacol Ther. 2015 Feb;41(4):342-51. doi: 10.1111/apt.13055. Epub 2014 Dec 18.

Supplemental Content

Support Center